Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland

A J McMichael1, E Zafeiridi, M Ryan

  • 1Centre for Public Health, Institute for Clinical Sciences Block B, Queens University Belfast, Belfast, Northern Ireland.

Aging & Mental Health
|October 19, 2020
PubMed

Insights

High anticholinergic burden from medications increases mortality risk in dementia patients. Reducing this burden is crucial, especially for those in deprived areas, to improve dementia care outcomes.

Area of Science:

  • Gerontology
  • Clinical Pharmacy
  • Epidemiology

Background:

  • Anticholinergic burden (ACB) is the cumulative effect of anticholinergic medications.
  • Understanding ACB's impact on dementia patient mortality is vital for clinical practice.
  • Demographic predictors of ACB in dementia patients require further investigation.

Purpose of the Study:

  • To assess the influence of anticholinergic burden and specific anticholinergic drug types on mortality rates in Northern Ireland dementia patients.
  • To identify demographic characteristics that predict anticholinergic burden in individuals with dementia.

Main Methods:

  • Utilized prescribing data for 25,418 dementia patients (2010-2016).
  • Calculated anticholinergic burden based on prescribed anticholinergic drugs.
  • Employed Cox proportional hazard and multilevel regression models to analyze mortality and demographic predictors.

Main Results:

  • 15% of dementia patients had no anticholinergic burden.
  • Higher anticholinergic burden was significantly associated with increased mortality (HR = 1.59).
  • Urological and respiratory anticholinergic drugs significantly elevated mortality risks.
  • Lower anticholinergic burden was observed in dementia patients from less deprived areas.

Conclusions:

  • Minimizing anticholinergic burden is essential for improving outcomes in dementia patients.
  • Further research is needed to address the poorer prognosis for dementia patients in highly deprived areas.
Abstract

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
630
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
127
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
802
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.3K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
110
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K